论文部分内容阅读
目的探讨丙酸氟替卡松治疗哮喘与鼻炎的临床研究。方法将患者随机分为治疗组和对照组。治疗组给予丙酸氟替卡松吸入气雾剂和鼻喷剂,对照组给予丙酸氟替卡松吸入气雾剂。1、3、6个月复诊,询问治疗后患者自上次随访以来哮喘急性发作次数及无症状天数,PEF,并检查外周血中嗜酸性粒细胞,中性粒细胞,淋巴细胞计数,变应性鼻炎急性发作次数及无症状天数。结果经治疗后,治疗组哮喘急性发作次数,无症状天数,PEF,鼻炎急性发作次数,无症状天数较对照组明显减轻,差异有统计学意义(P<0.05);1、3、6月份治疗组血中嗜酸性粒细胞、中性粒细胞、淋巴细胞计数明显减少,差异有统计学意义(P<0.05)。结论丙酸氟替卡松吸入气雾剂可改善哮喘症状,丙酸氟替卡松鼻喷剂可改善过敏性鼻炎患者病状,吸入糖皮质激素可改善哮喘及过敏性鼻炎患者症状,上、下呼吸道疾病同时应用糖皮质激素可明显改善患者症状。
Objective To investigate the clinical study of fluticasone propionate in the treatment of asthma and rhinitis. Methods Patients were randomly divided into treatment group and control group. The treatment group was given fluticasone propionate inhalation aerosol and nasal spray, while the control group was given fluticasone propionate inhalation aerosol. One, three and six-month follow-up, and the number of acute exacerbations and asymptomatic days since the last follow-up in patients after treatment, PEF, and the eosinophils, neutrophils, lymphocyte counts, Acute rhinitis episodes and asymptomatic days. Results After treatment, the number of asthma exacerbation, the number of asymptomatic days, the number of acute exacerbations of PEF, rhinitis and the number of asymptomatic asthma in the treatment group were significantly decreased as compared with those in the control group (P <0.05). Treatment of 1,3,6 months The blood eosinophils, neutrophils, lymphocytes count decreased significantly, the difference was statistically significant (P <0.05). Conclusion Fluticasone propionate inhalation aerosol can improve asthma symptoms, fluticasone propionate nasal spray can improve the symptoms of allergic rhinitis patients, inhaled corticosteroids can improve the symptoms of asthma and allergic rhinitis, upper and lower respiratory diseases while glucocorticoid Hormone can significantly improve the patient’s symptoms.